Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Claritin-D 12-Hour ER (SAG vs Heist) in Healthy Adults
NCT03517943Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2018
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of loratadine and pseudoephedrine in allergic rhinitis (AR) and nasal congestion (2 arms), sponsored by Bayer. Primary endpoints: Area under the concentration-time curve from time 0 to the last measurable concentration and Maximum observed drug concentration. Started Apr 2018; status: completed.
02
Drugs
loratadinepseudoephedrine
03
Conditions
allergic rhinitis (AR)nasal congestion
Beyond the preview
Go deeper on NCT03517943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517943.